摘要
Objective To determine what percentage of women can be given individu alized co unseling based on genetic information, as single nucleotide polymorphisms (SNPs) are associated with risks and benefits of estrogen therapy and hormone therapy such as thrombosis, myocardial infarction, breast cancer, and bone protection. D esign Cross-sectional study. Setting Academic research institution. Patient(s) A consecutive series of 2,507 perimenopausal and postmenopausal women. Intervent ion(s) Peripheral venous puncture and multiplex polymerase chain reaction on a m icroarray system. Main outcome measure(s) Analysis of 22 SNPs of 17 genes: AGTMe t235Thr, APOECys112Arg, APOEArg158-Cys, COMTVal158Met, CYP17-34T >C, CYP191558 C >T, CYP19Arg264Cys, CYP1A16235T >C, CYP1A1Ile462Val, CYP1B1Leu432Val, CYP1B1A -sn453Ser, HSD17B1-27A >C, ER-αIVS-401T >C, prothrombin20210G >A, factor V Leiden, eNOS-786T >C, eNOSGlu298Asp, MRSer810L eu, MTHFR677C >T, PAI 15G >4G, SRD5A2Val89Leu, and VDRb >B. Result(s) Among the women in the study, 66%had at least two homozygous mutant SNPs of interest. A t hrombophilic disposition was found in 9.9%of women, and 23%of women had at lea st two SNPs associated with an increased risk of breast cancer (COMT, CYP17, CYP 19, CYP1A1, and CYP1B1). The SNPs predisposing women to cardiovascular pathologi es (e.g., APOE, AGT, eNOS, and PAI 1) were found in 12.3%of women. Carriage of SNPs predisposing to early postmenopausal bone loss and osteoporosis (ER-αand VDR) were found in 26.7%of women. Conclusion( s) These data suggest that the as sessment of SNPs associated with risks and benefits of estrogen/hormone therapy may be a new means to individualize counseling about and prescription of estroge n/hormone therapy in up to 66%of women.
Objective To determine what percentage of women can be given individu alized co unseling based on genetic information, as single nucleotide polymorphisms (SNPs) are associated with risks and benefits of estrogen therapy and hormone therapy such as thrombosis, myocardial infarction, breast cancer, and bone protection. D esign Cross-sectional study. Setting Academic research institution. Patient(s) A consecutive series of 2,507 perimenopausal and postmenopausal women. Intervent ion(s) Peripheral venous puncture and multiplex polymerase chain reaction on a m icroarray system. Main outcome measure(s) Analysis of 22 SNPs of 17 genes: AGTMe t235Thr, APOECys112Arg, APOEArg158-Cys, COMTVal158Met, CYP17-34T >C, CYP191558 C >T, CYP19Arg264Cys, CYP1A16235T >C, CYP1A1Ile462Val, CYP1B1Leu432Val, CYP1B1A -sn453Ser, HSD17B1-27A >C, ER-αIVS-401T >C, prothrombin20210G >A, factor V Leiden, eNOS-786T >C, eNOSGlu298Asp, MRSer810L eu, MTHFR677C >T, PAI 15G >4G, SRD5A2Val89Leu, and VDRb >B. Result(s) Among the women in the study, 66%had at least two homozygous mutant SNPs of interest. A t hrombophilic disposition was found in 9.9%of women, and 23%of women had at lea st two SNPs associated with an increased risk of breast cancer (COMT, CYP17, CYP 19, CYP1A1, and CYP1B1). The SNPs predisposing women to cardiovascular pathologi es (e.g., APOE, AGT, eNOS, and PAI 1) were found in 12.3%of women. Carriage of SNPs predisposing to early postmenopausal bone loss and osteoporosis (ER-αand VDR) were found in 26.7%of women. Conclusion( s) These data suggest that the as sessment of SNPs associated with risks and benefits of estrogen/hormone therapy may be a new means to individualize counseling about and prescription of estroge n/hormone therapy in up to 66%of women.
